BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Back to dashboard
Company Information
About this company
Key people
Steven Brown
Independent Chairman of the Board
Mika Grasso
Interim Chief Executive Officer, Director
Anna Skowron
Chief Financial Officer
Zachary Smith
Vice President - Biocosmeceuticals Division
Francisco Silva
Vice President - Research & Development, Secretary
Jatinder Dhaliwal
Independent Director
Esha Randhawa
Independent Director
Click to see more
Key facts
- Shares in issue1.38m
- EPICBRTX
- ISINUS0906557055
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.87m
- Employees13
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.